In a June 5 release, Claret Medical announced it had received regulatory clearance from the U.S. Food and Drug Administration for its Sentinel Cerebral Protection System. The device protects against stroke during transcatheter aortic valve replacement (TAVR) by capturing debris dislodged during the procedure.

A new study reports that emerging surgical techniques used to perform more extensive surgical repairs of type A dissection is improving long-term outcomes for patients.

Englishman John McCafferty holds the record as the world's longest surviving heart transplant patient. At the time of his surgery in the fall of 1982, physicians estimated he’d live five years. He lived another 30 on top of that—working, enjoying family, running half marathons, traveling, fundraising for a transplant support charity and trout fishing—before passing away just last summer.

The U.S. Food and Drug Administration (FDA) approved an expanded indication for the Sapien 3 Transcatheter Heart Valve, a move that will allow physicians to use the device to better treat patients with symptomatic heart disease.

St. John Hospital & Medical Center became the first facility in the United States to treat a high-risk patient with a heart pump and newly approved Tryton Side Branch Stent.

Claret Medical® today announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Sentinel™ Cerebral Protection System (CPS), via de novo classification, enabling U.S. commercialization of the device. The Sentinel is the first and only device available in the U.S. that offers protection against the risk of stroke by capturing and removing debris dislodged during transcatheter aortic valve replacement (TAVR) before it reaches the brain. In the pivotal SENTINEL randomized controlled trial, use of Sentinel reduced strokes by 63 percent in the first 72 hours after TAVR and maintained a substantial difference at 90 days.

New research from the University of Leeds in the United Kingdom challenges the established practice that all heart attack patients should be administered beta blockers to decrease heart activity and lower blood pressure.

A new study by the National Institutes of Health will explore the ways in which patients with HIV can avoid heart attacks, because one could be especially deadly for someone with the condition, reports the Baltimore Sun.